Cinclus Pharma Holding AB (publ) (FRA:J8P)

Market Cap	50.46M -25.8%
Revenue (ttm)	6.15M +1,373.9%
Net Income	-21.79M
EPS	-0.47
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.042
Previous Close	1.096
Day's Range	1.042 - 1.042
52-Week Range	0.948 - 1.792
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 19, 2026

About Cinclus Pharma Holding AB

Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company’s lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori. Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquar...

• Industry: Pharmaceutical Preparations
• Founded: 2014
• Employees: 17
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: J8P

Financial Performance

In 2025, Cinclus Pharma Holding AB's revenue was 57.47 million, an increase of 1154.80% compared to the previous year's 4.58 million. Losses were -183.97 million, 9.49% more than in 2024.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jul 20, 2026

Data Sources Report a data error